Aida Pharmaceuticals Inc
Aida Pharmaceuticals, Inc., together with its subsidiaries, engages in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China. It offers antibiotics, cardiovascular, and anti-cancer drugs. The company provides its products in the form of powder for injection; and liquid for intravenous injection, capsule, tablet,… Read more
Aida Pharmaceuticals Inc (AIDA) - Net Assets
Latest net assets as of September 2008: $17.34 Million USD
Based on the latest financial reports, Aida Pharmaceuticals Inc (AIDA) has net assets worth $17.34 Million USD as of September 2008.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($73.99 Million) and total liabilities ($56.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $17.34 Million |
| % of Total Assets | 23.44% |
| Annual Growth Rate | 47.03% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.73 |
Aida Pharmaceuticals Inc - Net Assets Trend (2004–2007)
This chart illustrates how Aida Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aida Pharmaceuticals Inc (2004–2007)
The table below shows the annual net assets of Aida Pharmaceuticals Inc from 2004 to 2007.
| Year | Net Assets | Change |
|---|---|---|
| 2007-12-31 | $21.19 Million | +36.43% |
| 2006-12-31 | $15.53 Million | +50.93% |
| 2005-12-31 | $10.29 Million | +54.25% |
| 2004-12-31 | $6.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aida Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 339.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2007)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $7.33 Million | 55.04% |
| Common Stock | $27.00K | 0.20% |
| Other Comprehensive Income | $755.57K | 5.67% |
| Other Components | $5.20 Million | 39.08% |
| Total Equity | $13.32 Million | 100.00% |
Aida Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Aida Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Axis Energy Corp
PINK:AXGC
|
$1.80 |
|
Forecastagility Corporation
PINK:FCGY
|
$1.81 |
|
USA Real Estate Holding Co
PINK:USTC
|
$1.81 |
|
Cannalink Inc
PINK:CNLK
|
$1.81 |
|
RDVA Inc
PINK:RDVA
|
$1.80 |
|
Medical Supply International USA Inc
PINK:MSIU
|
$1.80 |
|
Guaranty Financial Corporation
PINK:GFCJ
|
$1.80 |
|
ECOCASH HOLDINGS ZIMBABWE LIMITED
XZIM:EHZL
|
$1.74 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aida Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2006 to 2007, total equity changed from 10,352,218 to 13,316,821, a change of 2,964,603 (28.6%).
- Net income of 2,740,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 224,778.
Equity Change Factors (2006 to 2007)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $2.74 Million | +20.58% |
| Other Comprehensive Income | $224.78K | +1.69% |
| Other Changes | $-175.00 | -0.0% |
| Total Change | $- | 28.64% |
Book Value vs Market Value Analysis
This analysis compares Aida Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $0.22 | $0.00 | x |
| 2005-12-31 | $0.29 | $0.00 | x |
| 2006-12-31 | $0.40 | $0.00 | x |
| 2007-12-31 | $0.49 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aida Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.58%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.38%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 4.71x
- Recent ROE (20.58%) is below the historical average (22.11%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 31.99% | 10.45% | 0.62x | 4.94x | $1.12 Million |
| 2005 | 21.83% | 5.99% | 0.57x | 6.34x | $795.59K |
| 2006 | 14.05% | 4.91% | 0.55x | 5.20x | $418.78K |
| 2007 | 20.58% | 9.38% | 0.47x | 4.71x | $1.41 Million |
Industry Comparison
This section compares Aida Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $608,648,365
- Average return on equity (ROE) among peers: -503.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aida Pharmaceuticals Inc (AIDA) | $17.34 Million | 31.99% | 3.27x | $1.80 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |